1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy

1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy

Abstract Background Myeloid derived suppresor cells (MDSC) are a heterogeneous population of immature myeloid cells that inhibits antitumor responses by T lymphocytes. High levels of MDSC have been found in the tumor microenvironment, which is correlated with a poor prognosis of the disease. Our pur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser: Cortegana, C Jiménez, Carrión, N Palazón, Fernández, E Nogales, García, M A Nieto, Margalet, V Sánchez, de la Gala, M D C Álamo, de Ilárduya, M Suengas Martínez, Burgos, E Montilla, Fernández, I Araújo, Carrasco, F Henao, García-Sancho, A Martín, Carnicero, F, Herranz, E Rios, de la Cruz Vicente, F, Fernández, R, Dominguez, A Rueda, de la Cruz Merino, L
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_5
container_start_page
container_title Annals of oncology
container_volume 30
creator Cortegana, C Jiménez
Carrión, N Palazón
Fernández, E Nogales
García, M A Nieto
Margalet, V Sánchez
de la Gala, M D C Álamo
de Ilárduya, M Suengas Martínez
Burgos, E Montilla
Fernández, I Araújo
Carrasco, F Henao
García-Sancho, A Martín
Carnicero, F
Herranz, E Rios
de la Cruz Vicente, F
Fernández, R
Dominguez, A Rueda
de la Cruz Merino, L
description Abstract Background Myeloid derived suppresor cells (MDSC) are a heterogeneous population of immature myeloid cells that inhibits antitumor responses by T lymphocytes. High levels of MDSC have been found in the tumor microenvironment, which is correlated with a poor prognosis of the disease. Our purposes are to evaluate the objective response rate (ORR) to test the treatment efficacy and to show the decrease of MDSC in clinical benefit (CB) patients, that includes complete response (CR), partial response (PR) and stabilization of disease (SD), when compared with progression of disease (PD). Methods 58 patients diagnosed of R/R DLBCL who were not high dose chemotherapy and autologous bone narrow transplantation candidates were recruited from Spanish hospitals. The patients progressed to a prior R-CHOP therapy and had ECOG ≤ 1. They were treated with the R2-GDP chemotherapy schedule (rituximab, lenalidomide, gemcitabine, dexamethasone and cisplatin). Three peripheral blood analysis were carried out: basal, cycle 3 (C3) and end of induction (EI) by flow cytometry to determine the MDSC level. Results 30 patients obtained CB response to treatment (PR 11 patients, CR 14 patients and SD 5 patients) and 28 patients obtained PD. A remarkable decrease of MDSC is shown in the Table, except in PD patients. On the other hand, ORR was 69% at C3 (PR 53%+ CR 16%) and 66% at EI (PR 40% + CR 26%). Table:1267P MDSC levels (cells/uL) in CB (CR, PR, SD) and PD. Av: average; St: Standard Deviation; *: Statistically significant differences (P 
doi_str_mv 10.1093/annonc/mdz253.092
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdz253_092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdz253.092</oup_id><sourcerecordid>10.1093/annonc/mdz253.092</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdz253_0923</originalsourceid><addsrcrecordid>eNqVkM1OwzAQhC0EEuHnAbjtESTSOEmTkmtLEYceUMU9MvGmdeU_2U6k8GA8H27LC3Da0cxoVvoIecjpLKdNmTGtje4yxb-LqpzRprggSV7VTfpC5_klSaJTpouqnF-TG-8PlNK6KZqE_ORFvfhYj0YOQRgNpgc1oTSCpxydGJGDH6x16L1x0KGUHpjmYL4O2IWYQ4ys0T4KFhCEjoZk1iPPHPaOdcG4Cbjo-yF2JHM7hOVpCOSk7N4oBo_bbAuvm-Vq8wSWBYE6xC99QBfHOhSj0DsQSg3ahD06Zqc7ctUz6fH-796S57f15-o9NYNtrROKuanNaXtk057ZtGc27ZHEP-u_A0xy8Q</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Cortegana, C Jiménez ; Carrión, N Palazón ; Fernández, E Nogales ; García, M A Nieto ; Margalet, V Sánchez ; de la Gala, M D C Álamo ; de Ilárduya, M Suengas Martínez ; Burgos, E Montilla ; Fernández, I Araújo ; Carrasco, F Henao ; García-Sancho, A Martín ; Carnicero, F ; Herranz, E Rios ; de la Cruz Vicente, F ; Fernández, R ; Dominguez, A Rueda ; de la Cruz Merino, L</creator><creatorcontrib>Cortegana, C Jiménez ; Carrión, N Palazón ; Fernández, E Nogales ; García, M A Nieto ; Margalet, V Sánchez ; de la Gala, M D C Álamo ; de Ilárduya, M Suengas Martínez ; Burgos, E Montilla ; Fernández, I Araújo ; Carrasco, F Henao ; García-Sancho, A Martín ; Carnicero, F ; Herranz, E Rios ; de la Cruz Vicente, F ; Fernández, R ; Dominguez, A Rueda ; de la Cruz Merino, L</creatorcontrib><description>Abstract Background Myeloid derived suppresor cells (MDSC) are a heterogeneous population of immature myeloid cells that inhibits antitumor responses by T lymphocytes. High levels of MDSC have been found in the tumor microenvironment, which is correlated with a poor prognosis of the disease. Our purposes are to evaluate the objective response rate (ORR) to test the treatment efficacy and to show the decrease of MDSC in clinical benefit (CB) patients, that includes complete response (CR), partial response (PR) and stabilization of disease (SD), when compared with progression of disease (PD). Methods 58 patients diagnosed of R/R DLBCL who were not high dose chemotherapy and autologous bone narrow transplantation candidates were recruited from Spanish hospitals. The patients progressed to a prior R-CHOP therapy and had ECOG ≤ 1. They were treated with the R2-GDP chemotherapy schedule (rituximab, lenalidomide, gemcitabine, dexamethasone and cisplatin). Three peripheral blood analysis were carried out: basal, cycle 3 (C3) and end of induction (EI) by flow cytometry to determine the MDSC level. Results 30 patients obtained CB response to treatment (PR 11 patients, CR 14 patients and SD 5 patients) and 28 patients obtained PD. A remarkable decrease of MDSC is shown in the Table, except in PD patients. On the other hand, ORR was 69% at C3 (PR 53%+ CR 16%) and 66% at EI (PR 40% + CR 26%). Table:1267P MDSC levels (cells/uL) in CB (CR, PR, SD) and PD. Av: average; St: Standard Deviation; *: Statistically significant differences (P &lt; 0.05) compared with basalResponseBasal Av (St)C3 Av (St)EI Av (St)CB19.9 (4.0)10.0 (3.1)4.8 (2.1)*CR18.6 (4.9)12.4 (3.7)2.7 (1.1)*PR13.0 (3.2)4.5 (0.8)1.4 (0.5)*SD35.3 (14.8)18.8 (11.6)18.5 (9.2)PD10.7 (4.0)8.6 (2.4)12.2 (2.9) Conclusions The ORR obtained shown the treatment efficacy in R/R DLBCL to stimulate the immune system antitumor response, which explains the decrease of MDSC in all CB groups and a non-important increase in PD patients. Based on these results, MDSC seem to be an important therapeutic target against tumor progression, as well as being a potentially promising marker of response. Clinical trial identification EudraCT number: 2014-001620-29. Legal entity responsible for the study Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL). Funding Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL). Disclosure All authors have declared no conflicts of interest.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdz253.092</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2019-10, Vol.30 (Supplement_5)</ispartof><rights>European Society for Medical Oncology 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Cortegana, C Jiménez</creatorcontrib><creatorcontrib>Carrión, N Palazón</creatorcontrib><creatorcontrib>Fernández, E Nogales</creatorcontrib><creatorcontrib>García, M A Nieto</creatorcontrib><creatorcontrib>Margalet, V Sánchez</creatorcontrib><creatorcontrib>de la Gala, M D C Álamo</creatorcontrib><creatorcontrib>de Ilárduya, M Suengas Martínez</creatorcontrib><creatorcontrib>Burgos, E Montilla</creatorcontrib><creatorcontrib>Fernández, I Araújo</creatorcontrib><creatorcontrib>Carrasco, F Henao</creatorcontrib><creatorcontrib>García-Sancho, A Martín</creatorcontrib><creatorcontrib>Carnicero, F</creatorcontrib><creatorcontrib>Herranz, E Rios</creatorcontrib><creatorcontrib>de la Cruz Vicente, F</creatorcontrib><creatorcontrib>Fernández, R</creatorcontrib><creatorcontrib>Dominguez, A Rueda</creatorcontrib><creatorcontrib>de la Cruz Merino, L</creatorcontrib><title>1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy</title><title>Annals of oncology</title><description>Abstract Background Myeloid derived suppresor cells (MDSC) are a heterogeneous population of immature myeloid cells that inhibits antitumor responses by T lymphocytes. High levels of MDSC have been found in the tumor microenvironment, which is correlated with a poor prognosis of the disease. Our purposes are to evaluate the objective response rate (ORR) to test the treatment efficacy and to show the decrease of MDSC in clinical benefit (CB) patients, that includes complete response (CR), partial response (PR) and stabilization of disease (SD), when compared with progression of disease (PD). Methods 58 patients diagnosed of R/R DLBCL who were not high dose chemotherapy and autologous bone narrow transplantation candidates were recruited from Spanish hospitals. The patients progressed to a prior R-CHOP therapy and had ECOG ≤ 1. They were treated with the R2-GDP chemotherapy schedule (rituximab, lenalidomide, gemcitabine, dexamethasone and cisplatin). Three peripheral blood analysis were carried out: basal, cycle 3 (C3) and end of induction (EI) by flow cytometry to determine the MDSC level. Results 30 patients obtained CB response to treatment (PR 11 patients, CR 14 patients and SD 5 patients) and 28 patients obtained PD. A remarkable decrease of MDSC is shown in the Table, except in PD patients. On the other hand, ORR was 69% at C3 (PR 53%+ CR 16%) and 66% at EI (PR 40% + CR 26%). Table:1267P MDSC levels (cells/uL) in CB (CR, PR, SD) and PD. Av: average; St: Standard Deviation; *: Statistically significant differences (P &lt; 0.05) compared with basalResponseBasal Av (St)C3 Av (St)EI Av (St)CB19.9 (4.0)10.0 (3.1)4.8 (2.1)*CR18.6 (4.9)12.4 (3.7)2.7 (1.1)*PR13.0 (3.2)4.5 (0.8)1.4 (0.5)*SD35.3 (14.8)18.8 (11.6)18.5 (9.2)PD10.7 (4.0)8.6 (2.4)12.2 (2.9) Conclusions The ORR obtained shown the treatment efficacy in R/R DLBCL to stimulate the immune system antitumor response, which explains the decrease of MDSC in all CB groups and a non-important increase in PD patients. Based on these results, MDSC seem to be an important therapeutic target against tumor progression, as well as being a potentially promising marker of response. Clinical trial identification EudraCT number: 2014-001620-29. Legal entity responsible for the study Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL). Funding Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL). Disclosure All authors have declared no conflicts of interest.</description><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkM1OwzAQhC0EEuHnAbjtESTSOEmTkmtLEYceUMU9MvGmdeU_2U6k8GA8H27LC3Da0cxoVvoIecjpLKdNmTGtje4yxb-LqpzRprggSV7VTfpC5_klSaJTpouqnF-TG-8PlNK6KZqE_ORFvfhYj0YOQRgNpgc1oTSCpxydGJGDH6x16L1x0KGUHpjmYL4O2IWYQ4ys0T4KFhCEjoZk1iPPHPaOdcG4Cbjo-yF2JHM7hOVpCOSk7N4oBo_bbAuvm-Vq8wSWBYE6xC99QBfHOhSj0DsQSg3ahD06Zqc7ctUz6fH-796S57f15-o9NYNtrROKuanNaXtk057ZtGc27ZHEP-u_A0xy8Q</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Cortegana, C Jiménez</creator><creator>Carrión, N Palazón</creator><creator>Fernández, E Nogales</creator><creator>García, M A Nieto</creator><creator>Margalet, V Sánchez</creator><creator>de la Gala, M D C Álamo</creator><creator>de Ilárduya, M Suengas Martínez</creator><creator>Burgos, E Montilla</creator><creator>Fernández, I Araújo</creator><creator>Carrasco, F Henao</creator><creator>García-Sancho, A Martín</creator><creator>Carnicero, F</creator><creator>Herranz, E Rios</creator><creator>de la Cruz Vicente, F</creator><creator>Fernández, R</creator><creator>Dominguez, A Rueda</creator><creator>de la Cruz Merino, L</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20191001</creationdate><title>1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy</title><author>Cortegana, C Jiménez ; Carrión, N Palazón ; Fernández, E Nogales ; García, M A Nieto ; Margalet, V Sánchez ; de la Gala, M D C Álamo ; de Ilárduya, M Suengas Martínez ; Burgos, E Montilla ; Fernández, I Araújo ; Carrasco, F Henao ; García-Sancho, A Martín ; Carnicero, F ; Herranz, E Rios ; de la Cruz Vicente, F ; Fernández, R ; Dominguez, A Rueda ; de la Cruz Merino, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdz253_0923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cortegana, C Jiménez</creatorcontrib><creatorcontrib>Carrión, N Palazón</creatorcontrib><creatorcontrib>Fernández, E Nogales</creatorcontrib><creatorcontrib>García, M A Nieto</creatorcontrib><creatorcontrib>Margalet, V Sánchez</creatorcontrib><creatorcontrib>de la Gala, M D C Álamo</creatorcontrib><creatorcontrib>de Ilárduya, M Suengas Martínez</creatorcontrib><creatorcontrib>Burgos, E Montilla</creatorcontrib><creatorcontrib>Fernández, I Araújo</creatorcontrib><creatorcontrib>Carrasco, F Henao</creatorcontrib><creatorcontrib>García-Sancho, A Martín</creatorcontrib><creatorcontrib>Carnicero, F</creatorcontrib><creatorcontrib>Herranz, E Rios</creatorcontrib><creatorcontrib>de la Cruz Vicente, F</creatorcontrib><creatorcontrib>Fernández, R</creatorcontrib><creatorcontrib>Dominguez, A Rueda</creatorcontrib><creatorcontrib>de la Cruz Merino, L</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cortegana, C Jiménez</au><au>Carrión, N Palazón</au><au>Fernández, E Nogales</au><au>García, M A Nieto</au><au>Margalet, V Sánchez</au><au>de la Gala, M D C Álamo</au><au>de Ilárduya, M Suengas Martínez</au><au>Burgos, E Montilla</au><au>Fernández, I Araújo</au><au>Carrasco, F Henao</au><au>García-Sancho, A Martín</au><au>Carnicero, F</au><au>Herranz, E Rios</au><au>de la Cruz Vicente, F</au><au>Fernández, R</au><au>Dominguez, A Rueda</au><au>de la Cruz Merino, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy</atitle><jtitle>Annals of oncology</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>30</volume><issue>Supplement_5</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Abstract Background Myeloid derived suppresor cells (MDSC) are a heterogeneous population of immature myeloid cells that inhibits antitumor responses by T lymphocytes. High levels of MDSC have been found in the tumor microenvironment, which is correlated with a poor prognosis of the disease. Our purposes are to evaluate the objective response rate (ORR) to test the treatment efficacy and to show the decrease of MDSC in clinical benefit (CB) patients, that includes complete response (CR), partial response (PR) and stabilization of disease (SD), when compared with progression of disease (PD). Methods 58 patients diagnosed of R/R DLBCL who were not high dose chemotherapy and autologous bone narrow transplantation candidates were recruited from Spanish hospitals. The patients progressed to a prior R-CHOP therapy and had ECOG ≤ 1. They were treated with the R2-GDP chemotherapy schedule (rituximab, lenalidomide, gemcitabine, dexamethasone and cisplatin). Three peripheral blood analysis were carried out: basal, cycle 3 (C3) and end of induction (EI) by flow cytometry to determine the MDSC level. Results 30 patients obtained CB response to treatment (PR 11 patients, CR 14 patients and SD 5 patients) and 28 patients obtained PD. A remarkable decrease of MDSC is shown in the Table, except in PD patients. On the other hand, ORR was 69% at C3 (PR 53%+ CR 16%) and 66% at EI (PR 40% + CR 26%). Table:1267P MDSC levels (cells/uL) in CB (CR, PR, SD) and PD. Av: average; St: Standard Deviation; *: Statistically significant differences (P &lt; 0.05) compared with basalResponseBasal Av (St)C3 Av (St)EI Av (St)CB19.9 (4.0)10.0 (3.1)4.8 (2.1)*CR18.6 (4.9)12.4 (3.7)2.7 (1.1)*PR13.0 (3.2)4.5 (0.8)1.4 (0.5)*SD35.3 (14.8)18.8 (11.6)18.5 (9.2)PD10.7 (4.0)8.6 (2.4)12.2 (2.9) Conclusions The ORR obtained shown the treatment efficacy in R/R DLBCL to stimulate the immune system antitumor response, which explains the decrease of MDSC in all CB groups and a non-important increase in PD patients. Based on these results, MDSC seem to be an important therapeutic target against tumor progression, as well as being a potentially promising marker of response. Clinical trial identification EudraCT number: 2014-001620-29. Legal entity responsible for the study Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL). Funding Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL). Disclosure All authors have declared no conflicts of interest.</abstract><pub>Oxford University Press</pub><doi>10.1093/annonc/mdz253.092</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2019-10, Vol.30 (Supplement_5)
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdz253_092
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title 1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A16%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1267PEvolution%20of%20myeloid-derived%20suppressor%20cells%20and%20objective%20response%20rate%20in%20relapsed/refractory%20diffuse%20large%20B%20cell%20lymphoma%20(R/R%20DLBCL)%20patients%20after%20receiving%20immunotherapy&rft.jtitle=Annals%20of%20oncology&rft.au=Cortegana,%20C%20Jim%C3%A9nez&rft.date=2019-10-01&rft.volume=30&rft.issue=Supplement_5&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdz253.092&rft_dat=%3Coup%3E10.1093/annonc/mdz253.092%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdz253.092&rfr_iscdi=true